prohibited list raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-28. Anything still debated is marked as such rather than presented as settled.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
=== Natural processes === There are over 30 collagens in nature that are similar in chemical composition but differ in terms of crystal structure. By far, collagen I and II are the most abundant. They initiatively form fibrils in vitro, while fibronectin, fibronectin-binding, collagen-binding integrins and collagen V are essential for collagen I forming and collagen XI for collagen II forming. Therefore, cellular mechanisms play key role in the protein self-assembly process.
Radium (88Ra) has no stable or nearly stable isotopes, and thus a standard atomic weight cannot be given. The longest lived, and most common, isotope of radium is 226Ra with a half-life of 1600 years, which is in the decay chain of 238U (the uranium or radium series). Radium now has 34 known isotopes from 201Ra to 234Ra. In the early history of the study of radioactivity, the different natural isotopes of radium were given different names (as were those of other radioactive elements), as it was not until Frederick Soddy's scientific work in the 1900s and 1910s that the concept of isotopes was employed. In this scheme, 223Ra was named actinium X (AcX), 224Ra thorium X (ThX), 226Ra radium (Ra), and 228Ra mesothorium 1 (MsTh1). When it was realized that all of these are isotopes of the same element, many of these names fell out of use, and "radium" came to refer to all isotopes, not just 226Ra, though mesothorium 1 in particular was still used for some time, with a footnote explaining that it referred to 228Ra. The known decay products of radium-226 received historical names including "radium", starting with radium emanation and then ranging from radium A to radium G, with the letter indicating approximately how far they were down the chain from their parent. In 2013 it was discovered that the nucleus of radium-224 is pear-shaped. This was the first discovery of an asymmetrical nucleus.
Economists have frequently highlighted the risks of redundancies from AI, and speculated about unemployment if there is no adequate social policy for full employment. The Economist said in 2015 that "the worry that AI could do to white-collar jobs what steam power did to blue-collar ones during the Industrial Revolution" is "worth taking seriously". Jobs at extreme risk range from paralegals to fast food cooks, while job demand is likely to increase for care-related professions ranging from personal healthcare to the clergy. In July 2025, Ford CEO Jim Farley predicted that "artificial intelligence is going to replace literally half of all white-collar workers in the U.S." According to the Stanford Digital Economy Lab in 2026, early-career workers showed decreasing employment rates in some AI-exposed occupations. In April 2023, Rest of World reported that 70% of the jobs for Chinese video game illustrators had been eliminated by generative artificial intelligence.
Sources: en.wikipedia.org
Berlin, Germany (suspended because of the Russo-Ukrainian war) Brno, Czech Republic (terminated because of the Russo-Ukrainian war) Chicago, United States (suspended because of the Russo-Ukrainian war) Düsseldorf, Germany (suspended because of the Russo-Ukrainian war) Kharkiv, Ukraine Kyiv, Ukraine Prague, Czech Republic (suspended since 2014 because of the Russo-Ukrainian war) Tallinn, Estonia Vilnius, Lithuania Warsaw, Poland (terminated because of the Russo-Ukrainian war)
Plantains have more starch and less sugar compared to regular bananas, which is why they are mostly cooked before eating. They are typically boiled or fried when eaten green, and when processed, they can be made into flour and turned into baked products such as cakes, bread and pancakes. Green plantains can also be boiled and pureed and then used as thickeners for soups. The pulp of green plantain is typically hard, with the peel often so stiff that it must be cut with a knife to be removed. Mature, yellow plantains can be peeled like typical dessert bananas; the pulp is softer than in immature, green fruit and some of the starch has been converted to sugar. They can be eaten raw, but are not as flavorful as dessert bananas, so are usually cooked. When yellow plantains are fried, they tend to caramelize, turning a golden-brown color. They can also be boiled, baked, microwaved, or grilled over charcoal, either peeled or unpeeled. Plantains are a staple food in the tropical regions of the world, ranking as the tenth most important staple food in the world. As a staple, plantains are treated in much the same way as potatoes, with a similar neutral flavor and texture when the unripe fruit is cooked by steaming, boiling, or frying. Since they fruit all year, plantains are a reliable staple food, particularly in developing countries with inadequate food storage, preservation, and transportation technologies. In Africa, plantains and bananas provide more than 25 percent of the caloric requirements for over 70 million people.
He moved to the USA and was thereafter active as a senior researcher at the Rockefeller Institute for Medical Research in New York. There, he was the main specialist in protein chemistry and contributed to the great progress of the US in the area of molecular biology. Two eventual Nobel Prize winners (William Howard Stein and Stanford Moore), as well as numerous postdoctoral students (including Klaus H. Hofmann) worked in his laboratory. Bergmann is considered an important figure in synthetic organic chemistry and biochemistry. He specialized in decoding peptide structures, while also researching their synthesis. He died in the Mount Sinai Hospital, New York City, on 7 November 1944. He was elected in 1936 a fellow of the American Association for the Advancement of Science. Since 1980, the Max-Bergmann-Kreis (MBK) company of German peptide chemists awards the Bergmann golden medal for peptide science, with the first medal given to Zervas. In 2002 the Max Bergmann Center was created in Dresden.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.